Saracatinib and Alcohol Drinking
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 50 |
| Updated: | 2/14/2018 |
| Start Date: | May 9, 2017 |
| End Date: | June 2021 |
| Contact: | Dana Cavallo, PhD |
| Email: | dana.cavallo@yale.edu |
| Phone: | 203-974-7607 |
Fyn Kinase Inhibitors and Alcohol Drinking
The purpose of this study is to evaluate the effects of the study medication,
saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory
setting in which participants are given an initial drink of alcohol followed by the choice to
drink up to 12 more drinks over a three-hour period. The investigators hypothesize that
saracatinib will reduce craving and number of drinks consumed prior to and after exposure to
the initial drink of alcohol and during the three hour drinking period.
saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory
setting in which participants are given an initial drink of alcohol followed by the choice to
drink up to 12 more drinks over a three-hour period. The investigators hypothesize that
saracatinib will reduce craving and number of drinks consumed prior to and after exposure to
the initial drink of alcohol and during the three hour drinking period.
Inclusion Criteria:
- Ages 21-50
- Able to read English at 6th grade level or higher and to complete study evaluations
- Regular alcohol drinker
Exclusion Criteria:
- Individuals who are seeking alcohol treatment
- Medical conditions that would contraindicate the use of saracatinib
- Regular use of other substances
We found this trial at
1
site
New Haven, Connecticut 06519
Principal Investigator: Suchitra Krishnan-Sarin, Ph.D.
Phone: 203-974-7607
Click here to add this to my saved trials
